Psycho-immuno-endocrinology of the thyroid gland

Czech version

Authors: Ivan Šterzl; Karolína Absolonová; Petr Matucha
Authors‘ workplace: Oddělení klinické imunoendokrinologie Endokrinologického ústavu, Praha
Published in: Vnitř Lék 2016; 62(Suppl 3): 107-114
Category: Reviews

Overview

Historically endocrinologists and psychiatrists are aware that disturbances in thyroid disease in beginning or even in clinically intensified states of thyrotoxicosis or hypothyroidism exhibit pathological mental manifestations, masking or potentiating the underlying disease. Immune system disorders cause thyroid organ-specific autoimmune process. This autoimmune thyroid disease binds with a number of disorders in both endocrine or non-endocrine organs. This appears in vascular, neurological, skin, connective tissue, gastrointestinal tract and mental pathology. These disorders are part of autoimmune polyglandular syndromes (APS) type I –III, especially the APS type III. Originally it was assumed that these mental disorders are caused by direct exposure to excess or deficiency of thyroid hormones. Recently, however, it appears that these psycho-immune-endocrine disorders have common etiologic mechanisms of formation and on cellular and molecular level they involve similar, if not in some cases, common mechanisms.

Key words:
antithyroid peroxidase antibody – autoimmune polyglandular syndrome type I., II., III. – autoimmune thyroid disease – bipolar disorder – depression – Hashimoto’s encephalopathy – postpartum psychosis – psycho-immuno-endocrinology – schizophrenia

Sources

1. Gull WW. On cretinoid state supervening in adult life in women. Trans Clinical Society of London 1874; 7: 180–185.

2. Report of a Committee of the Clinical Society of London, Nominated December 14, 1883, to Investigate the Subject of Myxoedema. Trans Clinical Society of London 1888; (Suppl 21).

3. Wagner von Jauregg J. Myxödem und Kretinismus. In Handbuch der Psychiatrie. Deuticke: Leipzig – Wien 1912.

4. Wagner-Jauregg J Verhütung und Behandlung der progressiven Paralyse durch Impfmalaria. In: Handbuch der experimentellen Terapie-Ergänzungsband. München 1931.

5. Asher R. Myxoedematous madness. Br Med J 1949; 2(4627): 555–562.

6. Awad AG.The Thyroid and the Mind and Emotions -Thyroid Dysfunction and Mental Disorders. Thyrobulletin 1986; 7. Dostupné z WWW: http://www.thyroid.ca/e10f.php. [Rev. 2000].

7. Šterzl I. Přehledná imunoendokrinologie: patofyziologie, diagnostika, terapie. Maxdorf: Praha 2006. ISBN 80–7345–087–9.

8. Neufeld M, Blizzard R. Polyglandular autoimmune diseases. In: Pinchera A, Doniach D, Fenzi GF et al (eds). Symposium on autoimmune aspects of endocrine disorders. Academic Press: New York 1980: 357–365.

9. Peterson P, Perheentupa J, Krohn KJ. Detection of candidal antigens in autoimmune polyglandular syndrome type I. Clin Diagn Lab Immunol 1996; 3(3): 290–294.

10. Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed 2003; 74(1): 9–33.

11. Kyung Ae Lee, Kyung Taek Park, Hea Min Yu et al. Subacute thyroiditis presenting as acute psychosis: a case report and literature review. Korean J Intern Med 2013; 28(2): 242–246. Dostupné z DOI: <http://dx.doi.org/10.3904/kjim.2013.28.2.242>.

12. Bunevicius R, Steibliene V, Prange AJ Jr. Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study. BMC Psychiatry 2014; 14: 279. Dostupné z DOI: <http://dx.doi.org/10.1186/s12888–014–0279–7>.

13. Dratman MB. Cerebral versus peripheral regulation and utilization of thyroid hormones. In: Joffe RT, Levitt AJ (eds). The Thyroid Axis and Psychiatric Illness. American Psychiatric Press: Washington, DC 1993: 3–94. ISBN 978–0880483643.

14. Stern RA, Prange AJ Neuropsychiatric aspects of endocrine disorders. In: Kaplan HI, Sadock BJ (eds). 2 Voll. 2nd ed. Comprehensive Textbook of Psychiatry. Wiliams & Wilkins: Baltimore: 1995: 241–251. ISBN 978–0683045321.

15. Whybrow PC, Prange AJ Jr. A hypothesis of thyroid-catecholamine-receptor interaction: its relevance to affective illness. Arch Gen Psychiatry 1981; 38(1): 106–113.

16. Janine A, van Venrooij EM, Sjoerd BA et al. Impaired Neuroendocrine and Immune Response to Acute Stress in Medication-Naive Patients With a First Episode of Psychosis. Schizophr Bull 2012; 38(2): 272–279. Dostupné z DOI: <http://dx.doi.org/10.1093/schbul/sbq062>.

17. Cunningham-Rundles C. Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin Exp Immunol 2011; 164:(Suppl 2): 6–11. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2249.2011.04388.x>.

18. Etzioni A. Immune deficiency and autoimmunity. Autoimmun Rev 2003; 2(6): 364–369.

19. Sterzl I, Sterzl J. The genetic basis of primary, predominantly specific immunodeficiencies. Folia Biol (Praha) 1997; 43(6): 211–218.

20. Temmerman ST, Ma CA, Zhao Y et al. Defective nuclear IKKα function in patients with ectodermal dysplasia with immune deficiency. J Clin Invest 2012; 122(1): 315–326. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI42534>.

21. Yarandi SS, Peterson DA, Treisman GJ et al. Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases. J Neurogastroenterol Motil 2016; 22(2): 201–212. Dostupné z DOI: <http://dx.doi.org/10.5056/jnm15146>.

22. Logan AC, Jacka FN, Craig JM et al. The Microbiome and Mental Health: Looking Back, Moving Forward with Lessons from Allergic Diseases. Clin Psychopharmacol Neurosci 2016; 14(2): 131–147. Dostupné z DOI: <http://dx.doi.org/10.9758/cpn.2016.14.2.131>.

23. Boorman E, Zajkowska Z, Ahmed R et al. Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? Psychopharmacology (Berl) 2016; 233(9): 1591–1604. Dostupné z DOI: <http://dx.doi.org/10.1007/s00213–015–4105–9>.

24. Durinovic-Bello I, Schlosser M, Riedl M et al. Pro- and anti-inflammatory cytokine production by autoimmune T cells against preproinsulin in HLA-DRB1*04, DQ8 Type 1 diabetes. Diabetologia 2004; 47(3): 439–450.

25. Sugenyova A, Itoh N, Kasuga Y et al. Histopathological features of atrophic thyroiditis with blocking type-TSH binding inhibitor immunoglobulins. Endocr J 1995; 42(2): 277–281.

26. Martinez GJ, Nurieva RI, Yang XO et al. Regulation and function of proinflammatory TH17 cells. Ann NY Acad Sci 2008; 1143: 188–211. Dostupné z DOI: <http://dx.doi.org/10.1196/annals.1443.021>.

27. Miller A, Lider O, Roberts AB et al. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89(1): 421–425.

28. Rebuffat SA, Nguyen B, Robert B et al. Antithyroperoxidase antibody-dependent cytotoxicity in autoimmune thyroid disease. J Clin Endocrinol Metab 2008; 93(3): 929–934.

29. Marcocci C, Vitti P, Cetani F et al. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 1991; 72(1): 209–213.

30. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5(4): 285–294.

31. Biondi B, Cooper DC. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29(1): 76–131.

32. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988–1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87(2): 489–499.

33. Bocchetta A, Traccis F, Mosca E et al. Bipolar disorder and antithyroid antibodies: review and case series. Int J Bipolar Disord 2016; 4(1): 5. Dostupné z DOI: <http://dx.doi.org/10.1186/s40345–016–0046–4>.

34. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51(4): 305–311.

35. Shaw PJ, Walls TJ, Newman PK et al. Hashimoto’s encephalopathy: a steroid responsive disorder associated with high antithyroid antibody titre: report of 5 cases. Neurology 1991; 41(2 Pt 1): 228–233.

36. Wakai M, Nishikage H, Goshima K. Reversible white matter lesions and antithyroid antibodies in the cerebrospinal fluid in Hashimoto’s encephalopathy: a case report. Rinsho Shinkeigaku 2004; 44(7): 432–437.

37. Fatourechi V. Hashimoto’s encephalopathy: myth or reality? An endocrinologist’s perspective. Best Pract Res Clin Endocrinol Metab 2005; 19(1): 53–66.

38. Castillo P, Woodruff B, Caselli R et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63(2): 197–202.

39. Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci 2006; 18(1): 14–20.

40. Oliveira J, Hamdani N, Busson M et al. Association between toll-like receptor 2 gene diversity and early-onset bipolar disorder. J Affect Disord 2014; 165: 135–141. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jad.2014.04.059>.

41. Vonk R, van der Schot AC, Kahn RS et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 2007; 62: 135–140.

42. Šterzl I. Vliv vitaminu D na imunitní mechanismy. Interní Med 2014; 16(3): 110–112.

43. Müssig K, Bartels M, Gallwitz B et al. Hashimoto’s encephalopathy presenting with bipolar affective disorder. Bipolar Disord 2005; 7(3): 292–297.

44. Haggerty jr. JJ, Silva SG, Marquardt M et al. Prevalence of antithyroid antibodies in mood disorders. Depress Anxiety 1997; 5(2): 91–96.

45. Bocchetta A, Cocco F, Velluzzi F et al. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 2007; 30(5): 363–366.

46. Yoneda M, Fujii A, Ito A et al. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto’s encephalopathy. J Neuroimmunol 2007; 185(-2): 195–200.

47. Drexhage RC, Hoogenboezem TH, Versnel MA et al. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25(6): 1206–1213. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbi.2011.03.013>.

48. León-Caballero J, Pacchiarotti I, Murru A et al. Bipolar disorder and antibodies against the N-methyl-D-aspartate receptor: a gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. Neurosci Biobehav Rev 2015; 55: 403–412. Dostupné z DOI: <http://dx.doi.org/10.1016/j.neubiorev.2015.05.012>.

49. Kayser MS, Titulaer MJ, Gresa-Arribas N et al. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013; 70(9): 1133–1139.

50. Dickerson F, Stallings C, Vaughan C et al. Antibodies to the glutamate receptor in mania. Bipolar Disord 2012; 14: 547–553. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1399–5618.2012.01028.x>.

51. Pearlman DM, Najjar S. Meta-analysis of the association between N-methyl-D-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res 2014; 157(1–3): 249–258. Dostupné z DOI: <http://dx.doi.org/10.1016/j.schres.2014.05.001>.

52. Chiba Y, Katsuse O, Takahashi Y et al. Anti-glutamate receptor e2 antibodies in psychiatric patients with anti-thyroid autoantibodies – a prevalence study in Japan. Neurosci Lett 2013; 534: 217–222. Dostupné z DOI: <http://dx.doi.org/10.1016/j.neulet.2012.10.060>.

53. Nemeroff CB, Simon JS, Haggerty JJ et al. Antithyroid antibodies in depressed patients. Am J Psychiatry 1985; 142(7): 840–843.

54. Dratman MB, Crutchfield FL, Gordon JT et al. Idothyronine homeostasis in rat brain during hypo and hyperthyroidism. Am J Physiol 1983; 245(2): E185-E193.

55. Sata T, Imura E, Murata A et al. Thyroid hormone: catecholamine interrelationship during cold acclimation in rats: compensatory role of catecholamine for altered thyroid states. Acta Endocrinology (Copenh) 1986; 113(4): 536–542.

56. Chan BL, Singer W. The hypothalamic-pituitary-thyroid axis: clinical and theoretical principles. In: Joffe RT, Levitt AJ (eds). The Thyroid Axis and Psychiatric Illness. American Psychiatric Press: Washington, DC 1993: 147–168. ISBN 978–0880483643.

57. Martin-Subero M, Anderson G, Kanchanatawan B et al. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr 2016; 21(2): 184–198. Dostupné z DOI: <http://dx.doi.org/10.1017/S1092852915000449>.

58. Muller AF, Drexhage HA, Berghout A. Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: recent insights and consequences for antenatal and postnatal care. Endocr Rev 2001; 22(5): 605–630.

59. Harris B, Othman S, Davies JA et al. Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ 1992; 305 (6846): 152–156.

60. Pop VJ, Wijnen HA, Lapkienne L et al. The relation between gestational thyroid parameters and depression: a reflection of the downregulation of the immune system during pregnancy? Thyroid 2006; 16(5): 485–492.

61. Kashyap AS, Anand KP, Kashyap S. Postpartum psychiatric disorders. Lancet 2004; 363(9414): 1077–1078.

62. Bergink V, Kushner SA, Pop V et al. Prevalence of autoimmune thyroid dysfunction in postpartum psychosis. Br J Psychiatry. 2011; 198(4): 264–268. Dostupné z DOI: <http://dx.doi.org/10.1192/bjp.bp.110.082990>.

63. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine 2003; 21(24): 3352–3357.

64. Pop VJ, Wijnen HA, Lapkienne L et al. The relation between gestational thyroid parameters and depression: a reflection of the downregulation of the immune system during pregnancy? Thyroid 2006; 16(5): 485–492.

65. Weetman AP Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol 2010; 6(6): 311–318. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2010.46>.

66. Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab 2004; 18(2): 303–316.

67. Jones AL, Mowry BJ, Pender MP et al. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 2005; 83(1): 9–17.

68. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006; 27(2): 71–80.

69. Rogers DP, Goldsmith CA. Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev Neurother 2009; 9(1): 47–54. Dostupné z DOI: <http://dx.doi.org/10.1586/14737175.9.1.47>.

70. Kudoh A, Sakai T, Ishihara H et al. Plasma cytokine response to surgical stress in schizophrenic patients. Clin Exp Immunol 2001; 125(1): 89–93.

71. Goldsmith CA, Rogers DP. The case for autoimmunity in the etiology of schizophrenia. Pharmacotherapy 2008; 28(6): 730–741. Dostupné z DOI: <http://dx.doi.org/10.1592/phco.28.6.730>.

72. Muller N, Schwarz MJ. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 2): 97–106. Dostupné z DOI: <http://dx.doi.org/10.1007/s00406–008–2012–3>.

73. Sperner-Unterweger B, Whitworth A, Kemmler G et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr Res 1999; 38(1): 61–70.

74. Yovel G, Sirota P, Mazeh D et al. Higher natural killer cell activity in schizophrenic patients: the impact of serum factors, medication, and smoking. Brain Behav Immun 2000; 14(3): 153–169.